$ERAS

Erasca, Inc.

Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its strategy is to target pathway signaling nodes, RAS directly and treatment escape routes, using single agents and combinations. The company’s modality-agnostic pipeline includes clinical-stage ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as ERAS-12, a discovery-stage EGFR D2/D3 biparatopic antibody program with an identified lead candidate. Erasca develops medicines internally and sources programs through licensing and acquisitions. It is studying ERAS-0015 and ERAS-4001 in clinical trials, and intends to commercialize its product candidates in the United States while exploring partnerships in selected geographies. It also has a wholly-owned subsidiary, Erasca Ventures, which makes equity investments in early-stage biotechnology companies aligned with its mission and strategy.

6
0
2

No SEC Form 4 filings for $ERAS in the last 30 days.

See all $ERAS insider activity →
Med

Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer

Erasca (ERAS) and Bristol Myers Squibb (BMY) will collaborate on a Phase 1/2 trial to study ERAS-0015 and navlimetostat in MTAP-deleted pancreatic cancer. ERAS-0015 targets RAS, while navlimetostat inhibits PRMT5. Erasca will supply the drug, and BMY will sponsor the study. ERAS stock closed at $13.89, up 3.05% in after-hours trading.

Why is Erasca stock sliding today?

Erasca (ERAS) stock fell 4.9% to $14.375 after HC Wainwright widened its FY2027-FY2030 loss forecasts. Leerink initiated coverage with an Outperform rating and $35 target, but the positive outlook was overshadowed by the downgrade and insider selling. The broader market decline also contributed to the sell-off.

Erasca GAAP EPS of -$0.15 misses by $0.01

Erasca reported Q3 GAAP EPS of -$0.15, missing estimates by $0.01. The company's cash and marketable securities totaled $947.8 million as of September 30, 2026, up from $341.8 million at the end of 2025. Erasca believes its current cash position will support upcoming milestones.

ERAS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ERAS (Erasca, Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 2 bearish.

Recent ERAS coverage spans financial news, earnings and market movers.

What's driving ERAS

AlphAI scores every news story that mentions ERAS with an AI model for sentiment and relevance, and aggregates insider trades from Erasca, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ERAS

Score

Why is Erasca stock sliding today?

Erasca (ERAS) stock fell 4.9% to $14.375 after HC Wainwright widened its FY2027-FY2030 loss forecasts. Leerink initiated coverage with an Outperform rating and $35 target, but the positive outlook was overshadowed by the downgrade and insider selling. The broader market decline also contributed to the sell-off.

$ERASHighAI 8/10Earnings

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Erasca Reports Third Quarter 2026 Business Updates and Financial Results ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS

Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.

$ERASLowExec change· terminated

Erasca, Inc. (ERAS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the developme

Related tickers